SEOM clinical guideline for the management of immune-related adverse events in patients treated with immune checkpoint inhibitors (2019)

• M. Majem ^[1] ; E. García-Martínez ^[10] ; M. Martinez ^[2] ; E. Muñoz-Couselo ^[3] ; D. Rodriguez-Abreu ^[4] ; R. Alvarez ^[5] ; A. Arance ^[6] ; A. Berrocal ^[7] ; L. de la Cruz-Merino ^[8] ; J. A. Lopez-Martin ^[9]
  1. [1] Hospital de la Santa Creu i Sant Pau

     Hospital de la Santa Creu i Sant Pau

     Barcelona, España

     
  2. [2] Hospital del Mar

     Hospital del Mar

     Barcelona, España

     
  3. [3] Hospital Vall d'Hebron

     Hospital Vall d'Hebron

     Barcelona, España

     
  4. [4] Complejo Hospitalario Universitario Insular - Materno Infantil de Canarias

     Complejo Hospitalario Universitario Insular - Materno Infantil de Canarias

     Gran Canaria, España

     
  5. [5] Hospital Virgen de la Salud

     Hospital Virgen de la Salud

     Toledo, España

     
  6. [6] Hospital Clinic Barcelona

     Hospital Clinic Barcelona

     Barcelona, España

     
  7. [7] Hospital General Universitario de Valencia

     Hospital General Universitario de Valencia

     Valencia, España

     
  8. [8] Hospital Universitario Virgen Macarena

     Hospital Universitario Virgen Macarena

     Sevilla, España

     
  9. [9] Hospital Universitario 12 de Octubre

     Hospital Universitario 12 de Octubre

     Madrid, España

     
  10. [10] Hospital Universitario Morales Meseguer

  Mostrar afiliaciones +
• Localización: Clinical & translational oncology, ISSN 1699-048X, Vol. 22, Nº. 2 (February), 2020 (Ejemplar dedicado a: Clinical Guides in Oncology), págs. 213-222
• Idioma: inglés
• Texto completo no disponible (Saber más ...)
• Resumen

  • The use of immune checkpoint inhibitors has emerged as an effective treatment option for patients with several tumor types. By increasing the activity of the immune system, they can induce inflammatory side effects, which are often termed immune-related adverse events. These are pathophysiologically unique toxicities, compared with those from other anticancer therapies. In addition, the spectrum of the target organs is very broad. Immune-inflammatory adverse events can be life threatening. Prompt diagnosis and pharmacological intervention are instrumental to avoid progression to severe manifestations. Consequently, clinicians require new skills to successfully diagnose and manage these events. These SEOM guidelines have been developed with the consensus of ten medical oncologists. Relevant studies published in peer-review journals were used for the guideline elaboration. The Infectious Diseases Society of America grading system was used to assign levels of evidence and grades of recommendation.